Volume 89, Issue 3
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645



In this randomized, double-blinded Phase 2 trial, 30 patients with cutaneous leishmaniasis were randomly allocated (1:1) to receive once daily topical treatment with WR 279,396 (15% paromomycin + 0.5% gentamicin) or Paromomycin Alone (15% paromomycin) for 20 days. The index lesion cure rate after 6 months follow-up was 13 of 15 (87%) for WR 279,396 and 9 of 15 (60%) for Paromomycin Alone ( = 0.099). When all treated lesions were included, the final cure rate for WR 279,398-treated patients was again 87%, but the final cure rate for Paromomycin Alone-treated patients was 8 of 15 (53.3%; = 0.046). Both creams were well tolerated with mild application site reactions being the most frequent adverse event. The increased final cure rate in the WR 279,396 group in this small Phase 2 study suggests that the combination product may provide greater clinical benefit than paromomycin monotherapy against cutaneous leishmaniasis.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.


Article metrics loading...

Loading full text...

Full text loading...



  1. WHO, 2010. Control of the leishmaniases. Report of a meeting of the WHO Expert Committee on the Control of Leishmaniases, Geneva, 22–26 March 2010. WHO Technical Report Series 949.
  2. University of Texas Southwestern Medical Center, 2008. Dermatologists Identify North Texas Leishmaniasis Outbreak. New Release DALLAS—September 14, 2007. Available at: http://www.utsouthwestern.edu/utsw/cda/dept353744/files/411952.html. Accessed 15 August 2012.
  3. Pehoushek JE, Quinn DM, Crum WP, , 2004. Cutaneous leishmaniasis in soldiers returning from deployment to Iraq. J Am Acad Dermatol 51: S125S128.[Crossref]
  4. Bern C, Maguire JH, Alvar J, , 2008. Complexities of assessing the disease burden attributable to leishmaniasis. PLoS Negl Trop Dis 2: e313.[Crossref]
  5. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK, , 2007. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 356: 25712581.[Crossref]
  6. Murray HW, Berman JD, Davies CR, Saravia NG, , 2005. Advances in leishmaniasis. Lancet 366: 15611577.[Crossref]
  7. Gonzalez U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA, , 2009. Interventions for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst Rev CD004834.
  8. Gonzalez U, Pinart M, Reveiz L, Alvar J, , 2008. Interventions for Old World cutaneous leishmaniasis. Cochrane Database Syst Rev CD005067.
  9. Grogl M, Schuster BG, Ellis WY, Berman JD, , 1999. Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin. J Parasitol 85: 354359.[Crossref]
  10. Ben Salah A, Buffet PA, Morizot G, Ben Massoud N, Zâatour A, Ben Alaya N, Haj Hamida NB, El Ahmadi Z, Downs MT, Smith PL, Dellagi K, Grögl M, , 2009. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: a phase 2, randomized, double blind, placebo controlled study. PLoS Negl Trop Dis 3: e432.[Crossref]
  11. Ben Salah A, Zakraoui H, Zaatour A, Ftaiti A, Zaafouri B, Garraoui A, Olliaro PL, Dellagi K, Ben Ismail R, , 1995. A randomized, placebo-controlled trial in Tunisia treating cutaneous leishmaniasis with paromomycin ointment. Am J Trop Med Hyg 53: 162166.
  12. de Brujin MH, Labrada LA, Smyth AJ, Santrich C, Barker DC, , 1993. A comparative study of diagnosis by the polymerase chain reaction and by current clinical methods using biopsies from Colombian patients with suspected leishmaniasis. Trop Med Parasitol 44: 201207.
  13. Vergel C, Walker J, Saravia NG, , 2005. Amplification of human DNA by primers targeted to Leishmania kinetoplast DNA and post-genome considerations in the detection of parasites by a polymerase chain reaction. Am J Trop Med Hyg 72: 423429.
  14. Reithinger R, Dujardin JC, , 2007. Molecular diagnosis of leishmaniasis: current status and future applications. J Clin Microbiol 45: 2125.[Crossref]
  15. Garra G, Singer AJ, Taira BR, Chohan J, Cardoz H, Chisena E, Thode HC, Jr, 2010. Validation of the Wong-Baker FACES Pain Rating Scale in pediatric emergency department patients. Acad Emerg Med 17: 5054.[Crossref]
  16. Campbell I, , 2007. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med 26: 36613675.[Crossref]
  17. Lydersen S, Fagerland MW, Laake P, , 2009. Recommended tests for association in 2 × 2 tables. Stat Med 28: 11591175.[Crossref]
  18. Daneshvar H, Burchmore R, Hagan P, Phillips RS, , 2009. Leishmania major H-line attenuated under pressure of gentamicin, induces a Th1 response which protects susceptible BALB/c mice against infection with virulent L. major . Parasitology 136: 12431250.[Crossref]
  19. Daneshvar H, Hagan P, Phillips RS, , 2003. Leishmania mexicana H-line attenuated under pressure of gentamicin, potentiates a Th1 response and control of cutaneous leishmaniasis in BALB/c mice. Parasite Immunol 25: 589596.[Crossref]
  20. Daneshvar H, Molaei MM, Kamiabi H, Burchmore R, Hagan P, Stephen Phillips R, , 2010. Gentamicin-attenuated Leishmania infantum: cellular immunity production and protection of dogs against experimental canine leishmaniasis. Parasite Immunol 32: 722730.[Crossref]
  21. Soto J, Fuya P, Herrera R, Berman J, , 1998. Topical paromomycin/methylbenzethonium chloride plus parenteral meglumine antimonate as treatment for American cutaneous leishmaniasis: controlled study. Clin Infect Dis 26: 5658.[Crossref]
  22. Arana BA, Mendoza CE, Rizzo NR, Kroeger A, , 2001. Randomized, controlled, double-blind trial of topical treatment of cutaneous leishmaniasis with paromomycin plus methylbenzethonium chloride ointment in Guatemala. Am J Trop Med Hyg 65: 466470.
  23. Soto-Mancipe J, Grogl M, Berman JD, , 1993. Evaluation of pentamidine for the treatment of cutaneous leishmaniasis in Colombia. Clin Infect Dis 16: 417425.[Crossref]
  24. Velez I, Agudelo S, Hendrickx E, Puerta J, Grogl M, Modabber F, Berman J, , 1997. Inefficacy of allopurinol as monotherapy for Colombian cutaneous leishmaniasis. A randomized, controlled trial. Ann Intern Med 126: 232236.[Crossref]
  25. Martinez S, Marr JJ, , 1992. Allopurinol in the treatment of American cutaneous leishmaniasis. N Engl J Med 326: 741744.[Crossref]
  26. Lopez-Jaramillo P, Rincon MY, Garcia RG, Silva SY, Smith E, Kampeerapappun P, García C, Smith DJ, López M, Vélez ID, , 2010. A controlled, randomized-blinded clinical trial to assess the efficacy of a nitric oxide releasing patch in the treatment of cutaneous leishmaniasis by Leishmania (V.) panamensis . Am J Trop Med Hyg 83: 97101.[Crossref]
  27. Garnier T, Croft SL, , 2002. Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs 3: 538544.
  28. El-Sayed M, Anwar AE, , 2009. Intralesional sodium stibogluconate alone or its combination with either intramuscular sodium stibogluconate or oral ketoconazole in the treatment of localized cutaneous leishmaniasis: a comparative study. J Eur Acad Dermatol Venereol 24: 335340.[Crossref]
  29. Willard RJ, Jeffcoat AM, Benson PM, Walsh DS, , 2005. Cutaneous leishmaniasis in soldiers from Fort Campbell, Kentucky returning from Operation Iraqi Freedom highlights diagnostic and therapeutic options. J Am Acad Dermatol 52: 977987.[Crossref]

Data & Media loading...

  • Received : 06 Dec 2012
  • Accepted : 06 Apr 2013

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error